Dihexa
A potent angiotensin IV analog studied for cognitive enhancement and potential treatment of neurodegenerative conditions.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is Dihexa?
Dihexa is a synthetic peptide analog of angiotensin IV that was developed at Washington State University. It has shown remarkable potency in animal models of cognitive enhancement — reported to be approximately 10 million times more potent than BDNF at promoting new neural connections. However, it remains in very early stages of research with no human clinical trials.
Why People Talk About It
Cognitive enhancement
PreliminaryMemory improvement
PreliminaryPotential for neurodegenerative conditions
LimitedHow It Works
Dihexa works by activating a receptor system (HGF/c-Met) that promotes the growth of new connections between brain cells. In animal studies, this has translated to improved memory and cognitive function, but human research has not been conducted.
Common Questions
Safety Information
Common Side Effects
Cautions
- • No human clinical trials
- • Theoretical concerns about promoting growth in neural tissue
- • Very early-stage research compound
- • Not appropriate for casual use
What We Don't Know
Essentially everything about human safety, dosing, and long-term effects is unknown. This is a research compound, not a therapy.
Published Research
5 studiesContributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer's Disease
Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia
Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway
Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Research Insights
Neuropeptides in 2026: Where the Research Actually Stands
Semax, Selank, Cerebrolysin, and Dihexa — separating clinical evidence from online hype in the cognitive enhancement space.
The Evidence Gap: Which Popular Peptides Have Almost No Human Data?
A frank look at the disconnect between online popularity and clinical evidence for some of the most discussed peptides.
Related Peptides
Quick Facts
- Class
- Angiotensin Analog
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Jan 2026
- Citations
- 5PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician